Quick Dispatch:
Your summit study tirzepatide Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your summit study tirzepatide Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial ships.
Need Help?
Questions about summit study tirzepatide Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for summit study tirzepatide Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial in your area.
At #ACC25, Dr. Milton Packer and colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of tirzepatide in patients with obesity, #HFpEF, and CKD. The trial demonstrated that #
28.23
Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity
25.44
In pts wiht HFpEF and obesity, tirzepatide (Mounjaro®) significantly reduces HF hospitalization, diuretic intensification, or CV death by 38% vs placebo in SUMMIT trial https://t.co/8ZHm4gySiL
25.74
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
24.92
Another "Positive" Heart Failure Trial that Falls Short
28.12
Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction
20.06
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
24.50
